

Technology appraisal (TA) Titles are hyperlinks to full guidance	Date of TA Release (N.B. if exact date is not specified in NICE documentation, the last day of the month published will be employed)	Adherence of local formulary to NICE				
		Yes (mark 'x' if applicable)	N/A (mark 'x' if applicable)	Date of local decision (DD/MM/YY)	Time to implement (days)	Notes (e.g. Additional stipulations, rationale, method of making available)
2016-17						
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer [TA439]	29/03/2017	x		18/04/2017	20	
Elotuzumab for previously treated multiple myeloma (terminated appraisal) [TA434]	22/03/2017		x	22/03/2017	0	
Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) [TA435]	22/03/2017		x	22/03/2017	0	
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) [TA436]	22/03/2017		x	22/03/2017	0	
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) [TA437]	22/03/2017		x	22/03/2017	0	
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) [TA438]	22/03/2017		x	22/03/2017	0	
Everolimus for advanced renal cell carcinoma after previous treatment [TA432]	22/02/2017	x		31/03/2017	37	
Apremilast for treating active psoriatic arthritis [TA433]	22/02/2017	x		20/04/2017	57	
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation [TA429]	25/01/2017	x		31/03/2017	65	
Sofosbuvir–velpatasvir for treating chronic hepatitis C [TA430]	25/01/2017	x		15/02/2017	21	
Mepolizumab for treating severe refractory eosinophilic asthma [TA431]	25/01/2017	x		31/03/2017	65	
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib [TA427]	11/01/2017	x		31/03/2017	79	
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy [TA428]	11/01/2017	x		31/03/2017	79	

Everolimus with exemestane for treating advanced breast cancer after endocrine therapy [TA421]	21/12/2016	x		17/01/2017	27	
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer [TA422]	21/12/2016	x		17/01/2017	27	
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens [TA423]	21/12/2016	x		17/01/2017	27	
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer [TA424]	21/12/2016	x		17/01/2017	27	
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia [TA425]	21/12/2016	x		17/01/2017	27	
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia [TA426]	21/12/2016	x		17/01/2017	27	
Ticagrelor for preventing atherothrombotic events after myocardial infarction [TA420]	14/12/2016	x		16/02/2017	64	
Nivolumab for previously treated advanced renal cell carcinoma [TA417]	23/11/2016	x		17/01/2017	55	
Dapagliflozin in triple therapy for treating type 2 diabetes [TA418]	23/11/2016	x		15/11/2016	-8	
Apremilast for treating moderate to severe plaque psoriasis [TA419]	23/11/2016	x		19/01/2017	57	
Elbasvir–grazoprevir for treating chronic hepatitis C [TA413]	26/10/2016	x		17/01/2017	83	
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [TA414]	26/10/2016	x		17/01/2017	83	
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor [TA415]	26/10/2016	x		17/01/2017	83	
Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer [TA416]	26/10/2016	x		17/01/2017	83	
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer [TA406]	28/09/2016	x		01/11/2016	34	
Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors [TA407]	28/09/2016	x		15/12/2016	78	
Pegaspargase for treating acute lymphoblastic leukaemia [TA408]	28/09/2016	x		01/11/2016	34	

Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion [TA409]	28/09/2016	x		01/11/2016	34	
Talimogene laherparepvec for treating unresectable metastatic melanoma [TA410]	28/09/2016	x		01/11/2016	34	
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer [TA411]	28/09/2016		x	28/09/2016	0	
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases [TA412]	28/09/2016	x		01/11/2016	34	
Bosutinib for previously treated chronic myeloid leukaemia [TA401]	24/08/2016	x		01/11/2016	69	
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin [TA402]	24/08/2016	x		01/11/2016	69	
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer [TA403]	24/08/2016	x		01/11/2016	69	
Degarelix for treating advanced hormone-dependent prostate cancer [TA404]	24/08/2016	x		20/10/2016	57	
Trifluridine–tipiracil for previously treated metastatic colorectal cancer [TA405]	24/08/2016	x		01/11/2016	69	
Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation [TA398]	27/07/2016		x	27/07/2016	0	
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts [TA399]	27/07/2016		x	27/07/2016	0	
Nivolumab in combination with ipilimumab for treating advanced melanoma [TA400]	27/07/2016	x		24/10/2016	89	
Adalimumab for treating moderate to severe hidradenitis suppurativa [TA392]	22/06/2016	x		19/07/2016	27	
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia [TA393]	22/06/2016	x		15/09/2016	85	
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia [TA394]	22/06/2016	x		15/09/2016	85	
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer [TA395]	22/06/2016	x		19/07/2016	27	
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma [TA396]	22/06/2016	x		19/07/2016	27	

Belimumab for treating active autoantibody-positive systemic lupus erythematosus [TA397]	22/06/2016	x		19/07/2016	27	
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes [TA390]	25/05/2016	X		16/06/2016	22	
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel [TA391]	25/05/2016	X		19/07/2016	55	
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction [TA388]	27/04/2016	X		19/05/2016	22	
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer [TA389]	26/04/2016	X		19/07/2016	84	
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated [TA387]	26/04/2016	X		19/07/2016	84	
		45	8			
		% "Yes"	% "N/A"	–	Average implement time	
Adherence statistics for 2016-17		85%	15%		43	